Topics
Period
recent search
Showing: 1 – 05 of 10 News
22 September 2025
22 September 2025
U.K. MHRA grants marketing authorisation for Cabozantinib Ipsen®– a first for previously treated advanced neuroendocrine tumours
LONDON, U.K., 22 SEPTEMBER 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for cabozantinib in adult patients with unresectable or metastatic, well differentiated pNETs and…
07 April 2025
07 April 2025
 accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease&media=https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/sites/19/2025/04/16173101/Wrexham-UK-img-03-hd-1-scaled.jpg "Share on LinkedIn")
LinkedIn
Facebook
The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease
LONDON, U.K., 7 April, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Scottish Medicines Consortium (SMC) has accepted elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response…
22 October 2024
22 October 2024
NICE recommends Ipsen’s IQIRVO® (elafibranor) – the first medicine approved for NHS use in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease
LONDON, U.K., 22 October, 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in…
08 October 2024
08 October 2024
U.K. MHRA grants marketing authorisation for Ipsen’s Iqirvo® (elafibranor), a first-in-class peroxisome proliferator-activated receptor (PPAR) treatment for primary biliary cholangitis (PBC)
LONDON, U.K., 8 October, 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for elafibranor 80mg tablets for the treatment of PBC in combination with UDCA…
07 March 2024
07 March 2024
Ipsen appoints Ioana Parsons as General Manager, U.K. & Ireland
LONDON, U.K., 6 March 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Ioana Parsons as General Manager of the company’s U.K. & Ireland affiliate. Ioana joins us from Ipsen Poland, where she has been General Manager…
CRSC-GB-000213
October 2025